Clinical trial
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00053391 · University Hospital Erlangen, Other · Completed
Key facts
| NCT number | NCT00053391 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma |
| Official title | Vaccination Of HLA-A1 And/Or -A2+ Stage III or IV Melanoma Patients With Tumor Peptide - Loaded Autologous Dendritic Cells That Are Generated In The Absence Or Presence Of CD40 Ligand |
| Lead sponsor | University Hospital Erlangen, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | recombinant CD40-ligand, therapeutic autologous dendritic cells |
| Enrollment | 62 |
| Start date | Oct 1, 2002 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Jan 28, 2003 |
| Last update posted | May 12, 2015 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: